Our results showed that HSF2 was dysregulated in various human cancers, which was consistent with previous studies from other clinical and preclinical data (Mustafa et al., 2010; Li et al., 2014; Björk et al., 2016; Zhong et al., 2016; Meng et al., 2017; Yang et al., 2018; Yang et al., 2019). This evidence concerns the gene HSF2 and cancer.